From ligand design to therapeutic efficacy: the challenge for nicotinic receptor research

B K Cassels, I Bermudez, F Dajas, J A Abin-Carriquiry, S Wonnacott

Research output: Contribution to journalArticle

  • 79 Citations

Abstract

S-Nicotine, the principal psychoactive constituent of Nicotiana tabacum, underpins addiction to tobacco smoking. Although tobacco consumption is a leading cause of death worldwide, nicotine itself is also proposed to have potential therapeutic benefits for a diverse range of conditions. Nicotine interacts with its cognate receptors in the central nervous system to exert a predominantly modulatory influence, making neuronal nicotinic receptors attractive therapeutic targets. Here, we focus on three natural products as lead compounds for drug discovery programs, nicotine, epibatidine and cytisine, and consider the aims and limitations that shape these drug discovery endeavors.
LanguageEnglish
Pages1657-1665
Number of pages9
JournalDrug Discovery Today
Volume10
Issue number23-24
DOIs
StatusPublished - Dec 2005

Fingerprint

Nicotinic Receptors
Nicotine
Ligands
epibatidine
Drug Discovery
Research
Tobacco Use
Therapeutics
Biological Products
Tobacco
Cause of Death
Central Nervous System
Smoking

Cite this

From ligand design to therapeutic efficacy: the challenge for nicotinic receptor research. / Cassels, B K; Bermudez, I; Dajas, F; Abin-Carriquiry, J A; Wonnacott, S.

In: Drug Discovery Today, Vol. 10, No. 23-24, 12.2005, p. 1657-1665.

Research output: Contribution to journalArticle

Cassels, BK, Bermudez, I, Dajas, F, Abin-Carriquiry, JA & Wonnacott, S 2005, 'From ligand design to therapeutic efficacy: the challenge for nicotinic receptor research' Drug Discovery Today, vol. 10, no. 23-24, pp. 1657-1665. DOI: 10.1016/S1359-6446(05)03665-2
Cassels BK, Bermudez I, Dajas F, Abin-Carriquiry JA, Wonnacott S. From ligand design to therapeutic efficacy: the challenge for nicotinic receptor research. Drug Discovery Today. 2005 Dec;10(23-24):1657-1665. Available from, DOI: 10.1016/S1359-6446(05)03665-2
Cassels, B K ; Bermudez, I ; Dajas, F ; Abin-Carriquiry, J A ; Wonnacott, S. / From ligand design to therapeutic efficacy: the challenge for nicotinic receptor research. In: Drug Discovery Today. 2005 ; Vol. 10, No. 23-24. pp. 1657-1665
@article{5210468bf8c04776b31607f1e53d3118,
title = "From ligand design to therapeutic efficacy: the challenge for nicotinic receptor research",
abstract = "S-Nicotine, the principal psychoactive constituent of Nicotiana tabacum, underpins addiction to tobacco smoking. Although tobacco consumption is a leading cause of death worldwide, nicotine itself is also proposed to have potential therapeutic benefits for a diverse range of conditions. Nicotine interacts with its cognate receptors in the central nervous system to exert a predominantly modulatory influence, making neuronal nicotinic receptors attractive therapeutic targets. Here, we focus on three natural products as lead compounds for drug discovery programs, nicotine, epibatidine and cytisine, and consider the aims and limitations that shape these drug discovery endeavors.",
author = "Cassels, {B K} and I Bermudez and F Dajas and Abin-Carriquiry, {J A} and S Wonnacott",
year = "2005",
month = "12",
doi = "10.1016/S1359-6446(05)03665-2",
language = "English",
volume = "10",
pages = "1657--1665",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier",
number = "23-24",

}

TY - JOUR

T1 - From ligand design to therapeutic efficacy: the challenge for nicotinic receptor research

AU - Cassels,B K

AU - Bermudez,I

AU - Dajas,F

AU - Abin-Carriquiry,J A

AU - Wonnacott,S

PY - 2005/12

Y1 - 2005/12

N2 - S-Nicotine, the principal psychoactive constituent of Nicotiana tabacum, underpins addiction to tobacco smoking. Although tobacco consumption is a leading cause of death worldwide, nicotine itself is also proposed to have potential therapeutic benefits for a diverse range of conditions. Nicotine interacts with its cognate receptors in the central nervous system to exert a predominantly modulatory influence, making neuronal nicotinic receptors attractive therapeutic targets. Here, we focus on three natural products as lead compounds for drug discovery programs, nicotine, epibatidine and cytisine, and consider the aims and limitations that shape these drug discovery endeavors.

AB - S-Nicotine, the principal psychoactive constituent of Nicotiana tabacum, underpins addiction to tobacco smoking. Although tobacco consumption is a leading cause of death worldwide, nicotine itself is also proposed to have potential therapeutic benefits for a diverse range of conditions. Nicotine interacts with its cognate receptors in the central nervous system to exert a predominantly modulatory influence, making neuronal nicotinic receptors attractive therapeutic targets. Here, we focus on three natural products as lead compounds for drug discovery programs, nicotine, epibatidine and cytisine, and consider the aims and limitations that shape these drug discovery endeavors.

UR - http://dx.doi.org/10.1016/S1359-6446(05)03665-2

U2 - 10.1016/S1359-6446(05)03665-2

DO - 10.1016/S1359-6446(05)03665-2

M3 - Article

VL - 10

SP - 1657

EP - 1665

JO - Drug Discovery Today

T2 - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 23-24

ER -